{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-001058","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2023-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.375639+00:00","generated_at":"2026-06-19T07:36:20.340153+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioCryst Q4 ORLADEYO revenue $70.7M; FY 2022 revenue $270.8M; 2023 guidance ≥$320M","bullets":["ORLADEYO net revenue $70.7M in Q4 2022, $251.6M for FY 2022; 2023 guidance no less than $320M.","Total Q4 revenue $79.5M (+68% YoY); net loss $71.5M ($0.38/share) vs $17.8M ($0.10) in Q4 2021 (incl. $55.8M gain).","Full year net loss $247.1M ($1.33/share) vs $184.1M ($1.03) in 2021; cash $443.9M at Dec 31, 2022.","Complement inhibitor program delayed due to nonclinical study observations; BCX10013 phase 1 showed >97% AP suppression.","ORLADEYO peak sales expected $1B; Canadian positive reimbursement recommendation received."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-001058","json":"https://secwatch.observer/filing/0001171843-23-001058.json","markdown":"https://secwatch.observer/filing/0001171843-23-001058.md","text":"https://secwatch.observer/filing/0001171843-23-001058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184323001058/0001171843-23-001058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184323001058/f8k_022123.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T07:36:20.340153+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"00bd65eae25ad257f8e48301697106d262ec073f","claim":"BIOCRYST PHARMACEUTICALS INC reported the fourth quarter and full year ended December 31, 2022 results: revenue $79.5 million, net income $71.5 million, or $0.38 per share, EPS $0.38 per share. Guidance reaffirmed.","evidence_excerpt":"molecules targeting C2, which are currently in lead optimization. Fourth Quarter 2022 Financial Results For the three months ended December 31, 2022, total revenues were $79.5 million, compared to $47.2 million in the fourth quarter of 2021 (+68 percent year-over-year). The increase was primarily due to $70.7 million in ORLADEYO net revenue in the fourth","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882796/000117184323001058/0001171843-23-001058-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Revenue","value":"$79.5 million"},{"label":"Net income","value":"$71.5 million, or $0.38 per share"},{"label":"EPS","value":"$0.38 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}